Cassava Sciences (SAVA) Stock: Buy, Sell, or Hold?
$2.38
+0.26 (+12.26%)
â˛
5d:
+7.21%
30d:
+17.24%
90d:
-26.99%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (87%)
Quality Score
48/100
Position
FAIR
Forward P/E & Valuation
-2.0x
Next 12M consensus est.
Wall Street Target
$8.00
+236.1% upside
Options IV & Volume
UNKNOWN Vol
UNKNOWN volume confirmation
Support / Resistance
$1.96 / $2.49
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: SAVA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When SAVA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: SAVA is currently trading at $2.38, which is considered fair based on recent price action.
Technical Outlook: Technically, SAVA is in a strong downtrend. Immediate support is located at $1.96, while resistance sits at $2.49. The stock is showing strong short-term momentum, up 12.3% recently.
Market Sentiment: SAVA scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.00 (+236.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SAVA is in a strong downtrend. Immediate support is located at $1.96, while resistance sits at $2.49. The stock is showing strong short-term momentum, up 12.3% recently.
Market Sentiment: SAVA scores 75/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $8.00 (+236.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Company Quality Score
48/100
(HOLD)
Volume Confirmation
UNKNOWN
Confidence Score
86.8%
Trading Range & Key Levels
Support Level
$1.96
Resistance Level
$2.49
Current Trend
Strong Downtrend
Technical data as of
Mar 10, 2026
Quantitative Signal Breakdown
- NEUTRAL: Price in fair range
- BULLISH: Strong technical setup (75/100)
- BULLISH: Strong upward momentum (+12.3%)
- BULLISH: Trading 236.1% below Wall St target ($8.00)
- WARNING: Composite score 48/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
-1.95
Wall Street Target
$8.00
(+236.1%)
Share SAVA Analysis
Share this live SAVA analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (SAVA)
Bearish
3 Retail Mentions
Reddit / WSB Comments
1
Bearish
StockTwits Volume
2 msgs
24h retail stream
Last Tracked
Sep 18, 2026
Daily AI digest
AI Retail Discussion Summary:
Cassava Sciences rebrands as Filana Therapeutics, focusing on developing medicines for filamin A-related CNS disorders, including TSC-related epilepsy. The new ticker symbol is 'FLNA'.
Key Retail Themes:
Company rebranding
Development of filamin A-modulating medicines for TSC-related epilepsy
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 11, 2026 8:10 PM ET
Data refreshes hourly during market hours. Next update: 9:10 PM
Data refreshes hourly during market hours. Next update: 9:10 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SAVA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
KYMR
Kymera Therapeutics Inc |
STRONG BUY
24 analysts |
$145 | 31 SELL |
|
ARGX
argenx NV ADR |
STRONG BUY
23 analysts |
$1147 | 35 SELL |
|
BNTX
BioNTech SE |
BUY
21 analysts |
$114 | 62 BUY |
|
IRD
Opus Genetics, Inc. |
STRONG BUY
18 analysts |
$13 | 41 HOLD |
|
MRUS
Merus BV |
STRONG BUY
17 analysts |
$97 | 39 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive SAVA Research Pages
